Comparable indicators of therapeutic misconception between epilepsy or Parkinson’s disease patients between those with clinical trial experience and trial non-participants

Clinical trials (CTs) are necessary for the development and approval of new medical therapies. A sufficient number of potentially enrolling study participants is a critical component of high CT quality. Attitudes toward CTs are positive among the general public and in various patient groups alike [1–3], yet recruitment of suitable patients may be challenging [4,5]. Altruism and a desire to contribute to science are major motivating factors for participation in CTs among patients with various disorders [3,6].